Curta

https://lnkd.in/g26r_qmJ Humacyte

?? AMCP 2025! ?? Curta is heading to Space City! ?? We’re excited have our award-winning research featured at AMCP 2025 in Houston, Texas—a city known for innovation, discovery, and of course, NASA’s Mission Control. In a city known for launching rockets, we’re launching groundbreaking research in managed care pharmacy—no space suit required! ????! Connect with Cynthia Gong for an in-person meet-up or with any of our Curta co-authors Elizabeth Brouwer, PhD MPH, Jimmy Tan, Cynthia Gong, Adam Kasle, or Brian Bloudek to learn more about our research. #CurtaResearch #AMCP2025 #SpaceCity #HealthcareInnovation #ManagedCarePharmacy

? ? ?? Helping Children Faster: Genome Sequencing Improves Diagnosis for Rare Pediatric Diseases. In this newly published paper, David Veenstra, Noemi (Fluetsch) Brennan, and Sarah Katsandres of Curta, along with colleagues from Illumina, conducted a systematic literature review and meta-analysis to evaluate the diagnostic yield and clinical utility of genome sequencing (GS) and exome sequencing (ES) in pediatric populations with rare and undiagnosed genetic diseases. This study is the first to evaluate the diagnostic yield of first-line GS use specifically, offering valuable insight into early genetic testing in the diagnostic journey of children with rare genetic diseases. Read more: https://lnkd.in/gcHfg5an

Mis-matched incentives and other challenges in biosimilar development and uptake threaten sustainability across global markets, risking drug shortages and stalling innovation. In newly published work, Curta researchers Tori Dayer and Sean Sullivan and colleagues outline a stakeholder-centered biosimilar market sustainability framework to inform research, shape policy agendas, and strategically address local, regional, and national decisions to align with long-term sustainability objectives. https://lnkd.in/grniarPi #biosimilars #HEOR #healtheconomics #curta

?? New Research Alert: Saving Life, Limb—and Maybe Some Cash ?? A study co-authored by Curta researchers Lucille Sun and Lisa Bloudek reveals that a novel bioengineered human arterial conduit could offer significant cost savings for trauma centers and insurers. Published in JME, the study explores how acellular tissue-engineered vessels (TEVs) may offer a cost-effective solution for repairing arterial injuries when autologous vein grafts aren’t feasible. The research suggests TEVs not only improve patient outcomes but could also reduce long-term healthcare costs—an innovation that benefits both patients and providers. Read more: https://lnkd.in/gBTa8DMn #HealthcareInnovation #MedicalResearch #TraumaCare #CostSavings #Bioengineering #HEOR

Curta at World EPA Congress 2025 – Let’s Connect! Curta leadership will be attending the World Evidence, Pricing, and Access (EPA) Congress in Amsterdam on March 5-6, 2025—Europe’s largest event dedicated to market access, pricing, and evidence in healthcare. With over 300 speakers, 1,500+ delegates, and 120+ exhibitors, this year’s event will feature discussions across nine key tracks, including Market Access, HTA, HEOR, Rare Diseases, and Real-World Evidence. The 2025 edition introduces a dedicated HEOR track and a poster area for deeper understanding of how HEOR can continue to support market access. We’re excited to participate in conversations shaping pricing, reimbursement, and market access strategies in Europe and the U.S. ?? Still a few meeting spots open! If you’d like to connect, reach out to schedule a time with Sean Sullivan or Lisa Bloudek See you in Amsterdam! ?? #MarketAccess #HEOR #Pricing #EPA2025 #HealthEconomics #Curta

?? Curta is hiring!?? We are seeking a full-time research associate or senior research associate with a focus on literature reviews. Check it out on our careers page: https://curta.com/careers/

This morning, CMS released their list of 15 Part D drugs to be negotiated in the next round of the Medicare Drug Price Negotiation Program. All 15 of the drugs are small molecules, 10 of the 15 have multiple indications, and only semaglutide has multiple brands (Ozempic, Rybelsus, and Wegovy). Back in September, we published our predictions of 13 drugs and identified 7 drugs with uncertain negotiation status to complete the list of 15. We correctly predicted 13 of the 15. We missed Otezla and Vraylar, which presumably have had recent increases in utilization since 2022. Sean Sullivan, Inmaculada (Inma) Hernandez, Ryan Hansen, Ayuri Kirihennedige, Nico Gabriel https://lnkd.in/g8tjynwu

We are seeking an SLR expert to join our team! The ideal candidate has hands-on experience with conducting SLRs for regulatory and HTA submission and with building and leading a team. Learn more at: https://lnkd.in/gzqfXAdy

We are seeking an experienced economic modeler to join our team! Ideal candidate has a solid history of developing models for global HTA submission, proficient in Excel and R, and enjoys throwing in some complex data analyses for variety! Learn more at: https://lnkd.in/gMyfu4_8